Medpace Holdings, Inc. $MEDP Shares Sold by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC decreased its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 18.9% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 41,015 shares of the company’s stock after selling 9,549 shares during the period. Janney Montgomery Scott LLC owned approximately 0.14% of Medpace worth $12,873,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in MEDP. Mawer Investment Management Ltd. acquired a new stake in shares of Medpace during the first quarter worth about $212,131,000. Vulcan Value Partners LLC raised its holdings in Medpace by 221.6% during the first quarter. Vulcan Value Partners LLC now owns 325,916 shares of the company’s stock worth $99,159,000 after purchasing an additional 224,578 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its holdings in Medpace by 675.8% during the first quarter. Jacobs Levy Equity Management Inc. now owns 121,464 shares of the company’s stock worth $37,009,000 after purchasing an additional 105,807 shares in the last quarter. Invesco Ltd. raised its holdings in Medpace by 9.4% during the first quarter. Invesco Ltd. now owns 1,186,768 shares of the company’s stock worth $361,596,000 after purchasing an additional 102,015 shares in the last quarter. Finally, Northern Trust Corp raised its holdings in Medpace by 36.0% during the first quarter. Northern Trust Corp now owns 337,489 shares of the company’s stock worth $102,830,000 after purchasing an additional 89,347 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Kevin M. Brady sold 12,000 shares of the firm’s stock in a transaction on Thursday, July 24th. The shares were sold at an average price of $454.23, for a total value of $5,450,760.00. Following the transaction, the chief financial officer owned 6,000 shares of the company’s stock, valued at approximately $2,725,380. This trade represents a 66.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO August J. Troendle sold 48,487 shares of the firm’s stock in a transaction on Monday, July 28th. The shares were sold at an average price of $451.69, for a total transaction of $21,901,093.03. Following the completion of the transaction, the chief executive officer directly owned 962,615 shares in the company, valued at approximately $434,803,569.35. This represents a 4.80% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 161,266 shares of company stock worth $74,111,427. 20.30% of the stock is owned by company insiders.

Medpace Stock Down 0.7%

Shares of MEDP opened at $532.49 on Friday. The company’s fifty day moving average is $474.84 and its two-hundred day moving average is $367.72. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $547.15. The firm has a market cap of $14.96 billion, a PE ratio of 39.59, a price-to-earnings-growth ratio of 3.37 and a beta of 1.40.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, July 21st. The company reported $3.10 EPS for the quarter, beating analysts’ consensus estimates of $3.00 by $0.10. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The business had revenue of $603.31 million for the quarter, compared to the consensus estimate of $537.70 million. During the same quarter last year, the firm posted $2.75 EPS. The business’s revenue for the quarter was up 14.2% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, equities research analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Analyst Ratings Changes

MEDP has been the subject of several analyst reports. Weiss Ratings reissued a “buy (b-)” rating on shares of Medpace in a report on Saturday, September 27th. Rothschild Redb cut shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 3rd. UBS Group cut shares of Medpace from a “neutral” rating to a “sell” rating and increased their price target for the stock from $300.00 to $305.00 in a report on Tuesday, July 29th. Mizuho increased their price target on shares of Medpace from $328.00 to $510.00 and gave the stock an “outperform” rating in a report on Friday, July 25th. Finally, TD Cowen reissued a “sell” rating and set a $366.00 price target (up from $283.00) on shares of Medpace in a report on Wednesday, July 23rd. Three investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $422.27.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.